OTCMKTS:UCBJFUCB Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $117.20 +1.50 (+1.30 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$117.20Now: $117.20▼$117.2050-Day Range$87.10MA: $101.95▼$118.7652-Week Range$67.39Now: $117.20▼$118.76Volume301 shsAverage Volume727 shsMarket Capitalization$22.80 billionP/E Ratio20.14Dividend YieldN/ABeta0.48 ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesSocial Media UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for UCB. Previous Next 2.3 Community Rank Outperform VotesUCB has received 225 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUCB has received 265 “underperform” votes. (Add your “underperform” vote.)Community SentimentUCB has received 54.08% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about UCB and other stocks. Vote “Outperform” if you believe UCBJF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UCBJF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUCB does not currently pay a dividend.Dividend GrowthUCB does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UCB insiders have not sold or bought any company stock. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for UCB are expected to grow by 16.61% in the coming year, from $5.72 to $6.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UCB is 20.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.08.Price to Earnings Ratio vs. SectorThe P/E ratio of UCB is 20.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.23.Price to Book Value per Share RatioUCB has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.71 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:UCBJF Previous Symbol CUSIPN/A CIKN/A Webwww.ucb.com Phone32-2559-9999Debt Debt-to-Equity Ratio0.14 Current Ratio1.38 Quick Ratio1.05Price-To-Earnings Trailing P/E Ratio20.14 Forward P/E Ratio20.49 P/E GrowthN/A Sales & Book Value Annual Sales$5.50 billion Price / Sales4.14 Cash Flow$5.68 per share Price / Cash Flow20.63 Book Value$40.36 per share Price / Book2.90Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees7,606 Outstanding Shares194,510,000Market Cap$22.80 billion Next Earnings Date7/27/2020 (Confirmed) OptionableNot Optionable OTC:UCBJF Rates by TradingView Receive UCBJF News and Ratings via Email Sign-up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter. UCB (OTCMKTS:UCBJF) Frequently Asked Questions How has UCB's stock been impacted by COVID-19 (Coronavirus)? UCB's stock was trading at $97.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UCBJF stock has increased by 20.6% and is now trading at $117.20. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of UCB? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for UCB. When is UCB's next earnings date? UCB is scheduled to release its next quarterly earnings announcement on Monday, July 27th 2020. View our earnings forecast for UCB. Has UCB been receiving favorable news coverage? Media headlines about UCBJF stock have trended negative this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. UCB earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the company's share price in the near future. View the latest news about UCB. Who are some of UCB's key competitors? Some companies that are related to UCB include Celgene (CELG), Vertex Pharmaceuticals (VRTX), Bayer (BAYRY), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY) and Merck KGaA (MKGAF). View all competitors. Who are UCB's key executives? UCB's management team includes the following people: Jean-Christophe Tellier, Chief Executive Officer & Executive DirectorCharl van Zyl, Chief Operating OfficerDetlef Thielgen, Chief Financial Officer & Executive Vice PresidentIris Löw-Friedrich, Chief Medical Officer & Executive Vice PresidentDhavalkumar Patel, Chief Scientific Officer & EVP What is UCB's stock symbol? UCB trades on the OTCMKTS under the ticker symbol "UCBJF." How do I buy shares of UCB? Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is UCB's stock price today? One share of UCBJF stock can currently be purchased for approximately $117.20. How big of a company is UCB? UCB has a market capitalization of $22.80 billion and generates $5.50 billion in revenue each year. The company earns $887.04 million in net income (profit) each year or $5.82 on an earnings per share basis. UCB employs 7,606 workers across the globe. What is UCB's official website? The official website for UCB is www.ucb.com. How can I contact UCB? UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected] This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
